drugset / Trial / NCT00381433

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

NCT00381433 ↗

Phase 1 Completed 12 enrolled Sarepta Therapeutics, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065, which was designed to target HCV, is also a PMO; its ability to cross the blood-brain barrier is unknown. In this study, a single dose of AVI-4065 will be subcutaneously injected, and samples collected to determine if this drug crosses the blood-brain barrier. If it does, then additional investigations could be performed in people with severe forms of HCV disease in which the brain is affected.

Timeline

Start
2006-09
Primary completion
2006-10
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AVI-4065 Oligonucleotide (other) — Subcutaneous

Indications